Product Code: PHA0422
In 2018, biobanking for research purposes was estimated at $2.2bn. The overall biobanking market is estimated to grow at a CAGR of 6.6% in the first half of the forecast period. The use of biobanks for therapeutic applications is also increasing, such as in the stem cell banking sector.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 276-page report you will receive 77 tables and 84 figures - all unavailable elsewhere.
The 276-page report provides clear detailed insight into the biobanking market. Discover the key drivers and challenges affecting the market.
Number of samples banked, revenues and growth forecasts from 2019 to 2029 for the global biobanking market
Number of samples banked, revenues and growth forecasts from 2019 to 2029 for the global biobanking market by application:
- Biobanking for research
- Biobanking for therapeutic use
Number of samples banked, revenues and growth forecasts from 2019 to 2029 for the research segment:
- Human tissues: Commercial, Public Sector
- Stem cells
- Other applications
Number of samples banked, revenues and growth forecasts from 2019 to 2029 for the therapeutic applications segment:
- Umbilical cord stem cell banking
- Adult stem cell banking
Revenues and growth forecasts from 2019 to 2029 for the biobanking market by product:
- Equipment: Freezers & Refrigerators, Cryogenic Storage Systems, Incubators & Centrifuges, Thawing Equipment, Temperature Control Systems, Alarms & Monitoring Systems
Revenue and growth forecasts from 2019 to 2029 for the global biobanking market by regional and national market:
- Leading EU countries - Germany, France, the UK, Italy, Spain and the Netherlands
- The BRIC countries - Brazil, Russia, India and China
- Discussion and profiles of the leading players in the biobanking industry. This report also provides a list of leading companies for each of the biobanking submarket.
- Provides and overview of technology used by biobanks. This includes systems, software, consumables and services. Prominent companies providing services are also discussed.
- Qualitative analyses of the biobanking industry, including industry trends, drivers and restrains, a SWOT analysis, a STEP analysis and Porter's Five Forces analysis of the biobanking market.
Key Questions Answered by this Report:
- How is the biobanking market evolving?
- What is driving and restraining biobanking market dynamics?
- How will each biobanking submarket segment grow over the forecast period and how much revenues will these submarkets account for in 2029?
- How will market shares of each biobanking submarket develop from 2018-2029?
- Which biobanking submarket will be the main driver of the overall market from 2018-2029?
- How will market shares of the national markets change by 2029 and which nation will lead the market in 2029?
- Who are the leading players?
- How will the sector evolve as alliances form during the period between 2018 and 2029?
Visiongain's study is intended for anyone requiring commercial analyses for the biobanking market. You find data, trends and predictions.
Buy our report today ‘Biobanking Market Forecasts 2019-2029: Research, Therapeutic, Human Tissue, Stem Cells, Commercial Sector, Public Sector, Umbilical Cord Banking, Adult Stem Cell Banking, Consumables, Equipment, Services, Freezers & Refrigerators, Cryogenic Storage Systems, Incubators & Centrifuges, Thawing Equipment, Temperature Control Systems, Alarms & Monitoring Systems’.
Visiongain is a trading partner with the US Federal Government.
Table of Contents
1. Report Overview
- 1.1 Biobanking for Therapeutics: World Market Review 2018 and Global Segmentation
- 1.2 Why You Should Read This Report
- 1.3 How This Report Delivers
- 1.4 Key Questions Answered by This Analytical Report
- 1.5 Who is This Report For?
- 1.6 Methodology
- 1.7 Frequently Asked Questions (FAQ)
- 1.8 Associated Visiongain Reports
- 1.9 About Visiongain
2. Introduction to Biobanking and its Applications
- 2.1 Defining the Human Tissue Banking Market for the Scope of this Report
- 2.2 The Stem Cell Banking Market - Our Breakdown
- 2.3 What is Biobanking?
- 2.4 Main Features of Biobanks
- 2.5 What Processes are Involved in Biobanking?
- 2.6 Classification of Biobanks: Tissue Type, Volunteer Group and Ownership Classification Models
- 2.6.1 Volunteer Group: General vs. Disease Population
- 2.6.2 Ownership Structure: Public vs. Private
- 2.7 Harmonization of Bio Banking and Initiatives Taken by Various Organizations
- 2.8 Biobank Funding and Financial Sustainability
- 2.9 The Guidelines and Standards for Biobanking
- 2.10 Laws and Regulations for Biobank-Based Research
- 2.11 Biobanking and the Pharmaceutical Industry
- 2.11.1 Biobanking in Research, Drug Discovery and Development
- 220.127.116.11 Biobanking - Facilitates Genetic Epidemiology Studies
- 18.104.22.168 Novel Drug Discovery through Better Understanding of Disease Pathways
- 22.214.171.124 Biomarker Discovery in Drug Development
- 2.11.2 Biobanking for Therapeutic Purposes
- 2.11.3 Biobanking in Clinical Trials
3. Global Biobanking Market 2019 to 2029
- 3.1 The World Biobanking Market in 2018
- 3.2 Biobanking for Therapeutics: Research vs. Therapeutics in 2024 and 2029
- 3.3 World Biobanking Market: Overarching Revenue Forecast 2019 to 2029
- 3.4 Biobanks Stored More Than 1.5 Billion Specimens in 2018
- 3.5 The Biobanking for Therapeutics Market by Sector: Grouped Revenue Forecasts 2019 to 2029
- 3.6 Biobanking for Research: Mostly Non-Profit
- 3.6.1 Biobanking for Research: Revenue Forecast 2019 to 2029
- 3.6.2 Driving Forces: Outweighs Restraints on the Biobanking Industry for Research
- 3.7 Biobanking for Future Therapeutic Use: Is It Too Commercial?
- 3.7.1 Arguments against Commercial Stem Cell Banking for Therapeutic Uses
- 3.7.2 Biobanking for Future Therapeutic Use: Revenue Forecast 2019 to 2029
- 3.7.3 Driving and Restraining Forces Influencing the Biobanking Market for Therapeutic Applications, 2019 to 2029
4. Biobanking for Research Purposes: World Market 2019 to 2029
- 4.1 Breakdown of Biobanking for Research Market by Tissue Type, 2018
- 4.2 Biobanking for Research in 2024 and 2029: Comparison by Tissue Type
- 4.3 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts 2019 to 2029
- 4.4 How Many Specimens are Biobanked for Research?
- 4.5 The Human Tissue Banking Market for Research in 2018
- 4.6 The Human Tissue Banking Market for Research: Revenue Forecast 2019 to 2029
- 4.7 The Human Tissue Banking Market: Commercial vs. Public Sector
- 4.7.1 Commercial Human Tissue Banks: Revenue Forecast 2019 to 2029
- 4.7.2 Public Sector Human Tissue Banks: Revenue Forecast 2019 to 2029
- 4.8 The Stem Cell Banking Market for Research in 2018
- 4.9 The Stem Cell Banking Market for Research: Revenue Forecast 2019 to 2029
- 4.9.1 R&D- Growing Interest Towards iPSCs
- 4.10 Banking of Other Biologics Specimens for Research in 2018
- 4.11 Banking of Other Biologic Specimens for Research: Revenue Forecast 2019 to 2029
5. Stem Cell Banking for Future Therapeutic Use: World Market 2019 to 2029
- 5.1 Stem Cell Banking for Therapeutic Use in 2018: A Breakdown by Stem Cell Type
- 5.2 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenue and Market Share, 2024 and 2029
- 5.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts
- 5.4 How Many Stem Cells Are Biobanked Each Year?
- 5.5 The Umbilical Cord Blood Banking Market in 2018
- 5.5.1 Private vs. Public Cord Blood Banking
- 5.5.2 Umbilical Cord Blood Banking: The Controversies
- 5.6 The Umbilical Cord Blood Banking Market: Revenue Forecast 2019 to 2029
- 5.7 The Adult Stem Cell Banking Market in 2018
- 5.8 The Adult Stem Cell Banking Market: Revenue Forecast 2019 to 2029
6. Global Biobanking Market by Product 2019 to 2029
- 6.1 The World Biobanking Market by Product in 2018
- 6.2 Biobanking Market by Product: 2024 and 2029
- 6.3 Consumables Market: Overarching Revenue Forecast 2019 to 2029
- 6.4 Equipment Market: Overarching Revenue Forecast 2019 to 2029
- 6.5 Services Market: Overarching Revenue Forecast 2019 to 2029
7. Leading National Markets 2019 to 2029
- 7.1 The Geographical Footprint of Biobanking
- 7.1.1 Biobanking in Europe: Leading the World with Biobanking Networks and Infrastructure
- 7.1.2 Biobanks in the US: A Fragmented Picture
- 7.1.3 Biobanking in Asia: A Region Fast Gaining Prominence
- 7.2 Biobanking for Therapeutics: The US Led the Way in 2018
- 7.3 The Leading National Markets: Grouped Revenue Forecasts 2019 to 2029
- 7.4 How Will Regional Market Shares Change to 2029?
- 7.5 The US Biobanking Market 2019 to 2029: Diversifying and Expanding
- 7.6 The Top European Biobanking Markets 2019 to 2029: Leading the Way in Biobanking Infrastructure
- 7.6.1 Germany: An Advanced Industry with 74 Biobanks Associated with the BBMRI
- 7.6.2 France: Restrictions on Private Stem Cell Banking Limit the Market
- 7.6.3 Italy: Is the Limited Private Stem Cell Banking Market Off-Set by Strong Biobanking Networks for Research?
- 7.6.4 UK: Limited Presence of Biobanking Networks
- 7.6.5 Spain: Controversy Between Private and Public Umbilical Cord Blood Banks
- 7.6.6 The Netherlands is Characterised by Comprehensive Biobanking Networks
- 7.7 The Japanese Biobanking Market 2019 to 2029: A High Level of Government Investment Drives Growth
- 7.8 The Biobanking Industry in the BRIC Countries: High Growth and Increasing Market Share between 2019 and 2029
- 7.8.1 The Chinese Biobanking Market 2019 to 2029: The High Rate of Growth Will Continue
- 7.8.2 The Indian Biobanking Market 2019 to 2029: Set to Become the Leading Market for Private Stem Cell Banking?
- 7.8.3 The Brazilian Biobanking Market 2019 to 2029: Will New Regulations Drive or Restrain the Market?
- 7.8.4 Russia: Ban on the Import and Export of Human Tissue and Genetic Information Restricts the Market, can this be Overcome?
8. Technology for Biobanking: Systems, Software, Consumables, and Services Associated with Biobanking
- 8.1 The Biobanking-Associated Market: Overview
- 8.2 Systems Technology: Fully Automated Handling
- 8.2.1 Automated Liquid Handling Systems
- 8.2.2 Frozen Aliquoting: Patented Technology from CryoXtract
- 8.2.3 Automated DNA Isolation
- 8.3 Storage Technology: Sustainability, Easy Sample Tracking, and Added Security
- 8.3.1 Dry State, Room Temperature Storage Eliminates the Need for Expensive, Energy-Consuming Freezers
- 8.3.2 Ultra-Low Temperature Freezers: Is Their Use Declining?
- 8.3.3 Cryopreservation: Mechanical vs. Liquid/ Vapour Phase Nitrogen
- 8.3.4 Automated Storage and Retrieval Systems: Essential Technology
- 8.3.5 RFID and Tagging Technology: Advantages over Barcodes
- 8.4 Software for Biobanks
- 8.4.1 Laboratory Information Management System (LIMS): Unmet Needs in the Market Remain, Despite Recent Advances
- 8.4.2 LIMS Functions
- 8.5 Consumables: High Quality Required for Effective Sample Management
- 8.5.1 Addressing Sample Storage and Tracking Issues
- 8.6 Biobanking Services: Storage, Management and Transport of Biologic Samples for a Fee
9. Leading Companies in the Biobanking Market, 2018
- 9.1 The Differing Business Models of Biobanking Companies: Sourcing vs. Storing
- 9.2 Leading Vendors of Biobanking Market 2018
- 9.2.1 Thermo Fisher Scientific, Inc.
- 126.96.36.199 Thermo Fisher Scientific: Financials 2015-2018
- 188.8.131.52 Strategic Developments
- 9.2.2 Merck KGaA
- 184.108.40.206 Merck KGaA: Financials 2015-2018
- 220.127.116.11 Strategic Developments
- 9.2.3 Qiagen
- 18.104.22.168 Qiagen: Financials 2015-2018
- 9.2.4 Danaher
- 22.214.171.124 Danaher: Financials 2015-2018
- 126.96.36.199 Strategic Developments
- 9.3 Commercial Biobanks for Research Purposes in 2018
- 9.3.1 Tissue Solutions: A Virtual Biobank with a Global Presence
- 9.3.2 An Overview of the Products and Services Offered by Tissue Solutions
- 9.3.3 Banked Samples Occur in Many Formats
- 9.3.4 Prospective Tissue Collection for Hard-to-Find Samples
- 9.3.5 Fresh Samples from Surgical Resections are in High Demand
- 9.3.6 Freshly Isolated Human Cells are a Valuable Research Tool
- 9.3.7 FDA/EMA Panel of Normal Tissues
- 9.3.8 Strengths, Capabilities and the Future Outlook for Tissue Solutions
- 9.3.9 Asterand Bioscience is now Part of Stemgent
- 188.8.131.52 Asterand's Products and Services: XpressBANK, BioSpoke and PhaseZERO
- 184.108.40.206 The Future Outlook for Asterand
- 9.3.10 Biopta: Human Tissue Provider Now Acquired by Japanese Company ReproCELL
- 220.127.116.11 Services from Biopta: A Variety of Lab Services and Fresh Tissue Sample Procurement
- 18.104.22.168 The First Catalogue of Assays Based on Human Functional Tissues
- 22.214.171.124 The Future Outlook for Biopta: Fresh Tissue Will Be in Demand
- 9.3.11 BioServe: One of the World's Largest Commercial Biorepositories
- 126.96.36.199 BioServe Offers a Comprehensive List of Services: Biobanking, Sourcing and Preclinical Molecular Services
- 188.8.131.52 The Future Outlook for BioServe
- 9.3.12 Coriell Institute for Medical Research: Reportedly the Largest Biobank in the World
- 184.108.40.206 Features of and Recent Developments at Coriell Biobank
- 220.127.116.11 Future Outlook for the Coriell Biobank
- 9.4 Prominent Biobanks for Therapeutic Use in 2018
- 9.4.1 Cord Blood America: Expansion into the Emerging Markets Apparently Stalled, Strategic Alternatives Being Considered
- 9.4.2 Cryo-Cell International: The First Private Cord Blood Bank in the Market
- 9.4.3 Cryo-Save's Educational Programme Benefits Company's Growth
- 9.4.4 China Cord Blood Corp: The Only Cord Blood Bank in China with Multiple Licences Is Under a New Owner
- 9.4.5 LifebankUSA: Acquisition from Human Longevity Inc Will Potentially Drive Growth
- 9.4.6 ViaCord: More Blood Units Released for Therapy than Any Other Family Bank
- 9.4.7 Cord Blood Registry: The World's Largest Newborn Stem Cell Company Will Be Promoted by New Parent Company
- 9.4.8 Biogenea Pharmaceuticals: A Comprehensive Offering of Stem Cell Banking Services across the Balkan Peninsula
- 9.4.9 StemLife is Reportedly Facing Challenges due to Government Regulations in Malaysia
- 9.4.10 Future Health Biobank: A Strong Market Presence Owing to International Operations
- 9.4.11 Caladrius Biosciences (formerly NeoStem): More Focus on Cell Therapy Than Stem Cell Banking
- 9.4.12 Precious Cells is Well Positioned to Take Advantage of the Growing Demand in India
10. Qualitative Analysis of the Biobanking Market 2019 to 2029
- 10.1 Industry Trends
- 10.1.1 The Growing Demand for Biobank Resources for Research
- 10.1.2 The Establishment of Biobanking Networks
- 10.1.2.1 BBMRI: The Most Extensive Biobank Network
- 10.1.3 Virtual Biobanks: Connecting a Fragmented Industry
- 10.1.4 Commercial Biobanks as Intermediaries: New Resources for Research
- 10.1.5 Automated Biobanking Has Become Imperative
- 10.1.6 Increasing Uptake of LIMS
- 10.1.7 Green Banking - Becoming More Energy Efficient
- 10.2 The Strengths and Weaknesses of the Biobanking Market in 2017
- 10.2.1 HBS are Valuable Resources for R&D
- 10.2.2 Governmental Support for Biobanking Forms a Strength of that Industry
- 10.2.3 Development of Potential Novel Stem Cell Therapies has Increased Public Awareness of Stem Cell Banking
- 10.2.4 The Effect of Big Data on Biobanking
- 10.2.5 Insufficient Accessible Numbers of High Quality Biospecimens
- 10.2.6 Biobanks are Fragmented and Uncoordinated
- 10.2.7 Lack of Standardisation is a Weakness of the Industry
- 10.2.8 Lack of Public Awareness Limits Number of Donors
- 10.2.9 Lack of Engagement with Public Health Services Limits the Stem Cell Banking Market
- 10.3 Opportunities and Threats Facing the Biobanking Market, 2019 to 2029
- 10.3.1 Increasing Use of Biobanked Specimens in Genome-Wide Association Studies (GWAS)
- 10.3.2 Increasing Demand for Biobanked Samples for Preclinical Research
- 10.3.3 Biobanking Networks as a Basis for Personalised Medicine
- 10.3.4 Options for Adult Stem Cell Banking Mean an Increasing Target Population for Private Stem Cell Banks
- 10.3.5 Even with Governmental Funding, Biobanks Must Become Self-Sufficient to Thrive Long-Term
- 10.3.6 Public Concerns over Confidentiality and Security Threaten Availability of Donors
- 10.3.7 Limitations Surrounding Informed Consent
- 10.4 Social, Technological, Economic and Political Factors (STEP) Influencing the Biobanking Industry, 2019 to 2029
- 10.5 Porters Five Forces Analysis, 2019 to 2029
- 10.5.1 Bargaining Power of Supplier: Low
- 10.5.2 Bargaining Power of Buyer: Moderate
- 10.5.3 Competitive Rivalry: High
- 10.5.4 Threat of New Entrants: Moderate
- 10.5.5 Threat of Substitutes: Low
- 11.1 World Biobanking Market 2019 to 2029: High Revenue Growth Predicted
- 11.2 Biobanking for Research 2019 to 2029: The Value of Biobanked Specimens is Increasingly Recognised
- 11.3 Biobanking for Therapeutic Use 2019 to 2029: Rapid Expansion in Adult Stem Cell Banking
- 11.4 The Leading National Markets: High Sales Growth Worldwide
- 11.5 Current and Future Trends in Biobanking
- 11.5.1 Increasing Demand for Biobanked Samples - Increasing Revenue
- 11.5.2 Improving Biobanking Infrastructure - Growth Driver and a Need for Strategic Planning for Sustainability
- 11.5.3 Marked Challenges, but Opportunities for Expansion
- Associated Visiongain Reports
- Visiongain Report Sales Order Form
- About Visiongain
- Visiongain Report Evaluation Form